![Evidence-Based Recommendations on the Use of Nirmatrelvir/Ritonavir (Paxlovid) for Adults in Ontario - Ontario COVID-19 Science Advisory Table Evidence-Based Recommendations on the Use of Nirmatrelvir/Ritonavir (Paxlovid) for Adults in Ontario - Ontario COVID-19 Science Advisory Table](https://covid19-sciencetable.ca/wp-content/uploads/2022/02/Table-4-1024x574.png)
Evidence-Based Recommendations on the Use of Nirmatrelvir/Ritonavir (Paxlovid) for Adults in Ontario - Ontario COVID-19 Science Advisory Table
![Ritonavir boosting of low-dose danoprevir (RG7227; ITMN-191), HCV NS3/4A protease inhibitor, results in robust reduction in HCV RNA at lower exposures than provided by unboosted regimens Ritonavir boosting of low-dose danoprevir (RG7227; ITMN-191), HCV NS3/4A protease inhibitor, results in robust reduction in HCV RNA at lower exposures than provided by unboosted regimens](https://www.natap.org/2010/images/041510/041510-6/image008.gif)
Ritonavir boosting of low-dose danoprevir (RG7227; ITMN-191), HCV NS3/4A protease inhibitor, results in robust reduction in HCV RNA at lower exposures than provided by unboosted regimens
![Structures of the boosters (CYP inhibitors) ritonavir and cobicistat,... | Download Scientific Diagram Structures of the boosters (CYP inhibitors) ritonavir and cobicistat,... | Download Scientific Diagram](https://www.researchgate.net/publication/338343436/figure/fig4/AS:842933066555398@1577982312337/Structures-of-the-boosters-CYP-inhibitors-ritonavir-and-cobicistat-and-selected.png)
Structures of the boosters (CYP inhibitors) ritonavir and cobicistat,... | Download Scientific Diagram
![HIV Protease Inhibitor Ritonavir Impairs Endothelial Function Via Reduction in Adipose Mass and Endothelial Leptin Receptor‐Dependent Increases in NADPH Oxidase 1 (Nox1), C‐C Chemokine Receptor Type 5 (CCR5), and Inflammation | Journal HIV Protease Inhibitor Ritonavir Impairs Endothelial Function Via Reduction in Adipose Mass and Endothelial Leptin Receptor‐Dependent Increases in NADPH Oxidase 1 (Nox1), C‐C Chemokine Receptor Type 5 (CCR5), and Inflammation | Journal](https://www.ahajournals.org/cms/asset/d9b9ed03-620a-4999-938a-478bf7b161e6/jah35534-fig-0007.png)
HIV Protease Inhibitor Ritonavir Impairs Endothelial Function Via Reduction in Adipose Mass and Endothelial Leptin Receptor‐Dependent Increases in NADPH Oxidase 1 (Nox1), C‐C Chemokine Receptor Type 5 (CCR5), and Inflammation | Journal
![Experimental COVID-19 Therapy Combination Lopinavir/Ritonavir Is Implicated in a Complicated Set of Drug-Drug Interactions - Anesthesia Patient Safety Foundation Experimental COVID-19 Therapy Combination Lopinavir/Ritonavir Is Implicated in a Complicated Set of Drug-Drug Interactions - Anesthesia Patient Safety Foundation](https://www.apsf.org/wp-content/uploads/ddi/2020/lopinavir-ritonavir.jpg)
Experimental COVID-19 Therapy Combination Lopinavir/Ritonavir Is Implicated in a Complicated Set of Drug-Drug Interactions - Anesthesia Patient Safety Foundation
![Dual therapy with ritonavir-boosted protease inhibitor (PI) plus lamivudine versus triple therapy with ritonavir-boosted PI plus two nucleos(t)ide reverse-transcriptase inhibitor in HIV-infected patients with viral suppression - ScienceDirect Dual therapy with ritonavir-boosted protease inhibitor (PI) plus lamivudine versus triple therapy with ritonavir-boosted PI plus two nucleos(t)ide reverse-transcriptase inhibitor in HIV-infected patients with viral suppression - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1684118219300866-gr1.jpg)
Dual therapy with ritonavir-boosted protease inhibitor (PI) plus lamivudine versus triple therapy with ritonavir-boosted PI plus two nucleos(t)ide reverse-transcriptase inhibitor in HIV-infected patients with viral suppression - ScienceDirect
![Enhancement of the Oral Availability of Cabazitaxel Using the Cytochrome P450 3A (CYP3A) Inhibitor Ritonavir in Mice | Molecular Pharmaceutics Enhancement of the Oral Availability of Cabazitaxel Using the Cytochrome P450 3A (CYP3A) Inhibitor Ritonavir in Mice | Molecular Pharmaceutics](https://pubs.acs.org/cms/10.1021/acs.molpharmaceut.2c01076/asset/images/large/mp2c01076_0007.jpeg)
Enhancement of the Oral Availability of Cabazitaxel Using the Cytochrome P450 3A (CYP3A) Inhibitor Ritonavir in Mice | Molecular Pharmaceutics
![Lopinavir–ritonavir super-boosting in young HIV-infected children on rifampicin-based tuberculosis therapy compared with lopinavir–ritonavir without rifampicin: a pharmacokinetic modelling and clinical study - The Lancet HIV Lopinavir–ritonavir super-boosting in young HIV-infected children on rifampicin-based tuberculosis therapy compared with lopinavir–ritonavir without rifampicin: a pharmacokinetic modelling and clinical study - The Lancet HIV](https://www.thelancet.com/cms/attachment/b672c9a6-b901-40c7-adc8-d4ab4380d4c9/gr1_lrg.jpg)
Lopinavir–ritonavir super-boosting in young HIV-infected children on rifampicin-based tuberculosis therapy compared with lopinavir–ritonavir without rifampicin: a pharmacokinetic modelling and clinical study - The Lancet HIV
![The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins - ScienceDirect The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0753332223004249-gr1.jpg)